Contrast-agent developer Epix Medical reported second-quarter revenues of $3.8 million, compared with $3.7 million recorded in the second quarter of 2002. For the period (end-June 30), the Cambridge, MA-based firm had a net loss of $3.6 million, compared with a net loss of $6.7 million reported for the quarter last year.
During the first half of fiscal 2003, Epix received $7.3 million in revenues, primarily from a product-development contract with Schering and a patent-licensing and royalty agreement from Bracco Imaging. Epix has also trimmed its net losses for the period compared with the first half of last year, posting a $9.1 million loss this year versus $11.3 million in 2002.
July 25, 2003
Related Reading
Epix completes final phase III trials on MRA contrast agent, July 11, 2003
Epix, Schering to partner on MRI contrast, May 27, 2003
Epix revenues gain, losses widen, April 25, 2003
Epix to develop new MR agent, April 1, 2003
Epix contrast agent clears second phase III trial, March 8, 2003
Copyright © 2003 AuntMinnie.com
